The University of Pennsylvania's participation in ECOG for the past 25 years has represented a combined effort among many individuals aimed at improving multi-modality care of cancer patients. The major activity of this group of physicians, nurses and data managers is directed towards innovative studies of new treatment approaches for a wide variety of cancers and hematologic malignancies. The University of Pennsylvania has established an outstanding ECOG administrative and scientific membership record in terms of senior leadership positions throughout ECOG and in the leadership of disease-oriented and modality-oriented committees of the Group. We have striven toward increasing patient accrual with high quality scientific data. In the development of protocols for the Group, we have worked towards an interdisciplinary team committed to cooperative group trials. Scientific contributions have been broad across all disciplines, involving chairmanship of major ECOG committees, leadership of group-wide ECOG protocols, and the development of pilot studies. During the projected grant period, it is expected that our scientific and administrative leadership will continue, and that our patient accrual will further increase. We will continue to expand our disease-specific orientation into pilot trials of innovative experimental approaches developed at the University of Pennsylvania Cancer Center. With the development of a new drug development program at the University of Pennsylvania Cancer Center. With the development of a new drug development program at the University of Pennsylvania, we expect to increase our pilot trial data, which can be brought forward into testing in the cooperative group setting. We will further expand our multi-modality research, including the active participation of radiation oncologists, surgical oncologists, urologists, and gynecologic oncologists. The University of Pennsylvania Cancer Center's intramural program of clinical research, patient care, and education works collaboratively with the goals of the Eastern Cooperative Oncology Group. In addition, the Cancer Center's community affiliates are strong participants in the ECOG affiliate program. The combined result of our ECOG and Cancer Center programs are therefore uniquely positioned to improve therapy for patients with malignant diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA015488-31
Application #
6632951
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2004-04-30
Budget Start
2003-05-01
Budget End
2004-04-30
Support Year
31
Fiscal Year
2003
Total Cost
$422,179
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Stock, W; Diouf, B; Crews, K R et al. (2017) An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 101:391-395
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel M et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75

Showing the most recent 10 out of 120 publications